The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Schizophrenia
Abstract
Schizophrenia involves multiple neurochemical pathways and brain circuits. Treatment is directed at ameliorating acute psychosis and reducing relapses. This review also discusses the use of psychosocial interventions and the management of medication effects of acute and tardive movement disorders and metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
A polygenic burden of rare disruptive mutations in schizophrenia
Purcell, S. M., Moran, J. L., Fromer, M., Ruderfer, D., Solovieff, N., Roussos, P., O’Dushlaine, C., Chambert, K., Bergen, S. E., Kähler, A., et al. (2014) · Nature · doi:10.1038/nature12975 · Cited by 1,385
Wykes, T., Steel, C., Everitt, B., & Tarrier, N. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm114 · Cited by 1,029
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Self-citationThe 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements
Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W., Lehman, A., Tenhula, W. N., Calmes, C., Pasillas, R. M., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp115 · Cited by 774
Synaptic mechanisms for plasticity in neocortex
Feldman, D. E. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135516 · Cited by 704
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Abnormal Rich Club Organization and Functional Brain Dynamics in Schizophrenia
van den Heuvel, M. P., Sporns, O., Collin, G., Scheewe, T., Mandl, R. C. W., Cahn, W., Goñi, J., Hulshoff Pol, H. E., & Kahn, R. S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1328 · Cited by 645
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Cannon, T. D., Chung, Y., He, G., Sun, D., Jacobson, A., van Erp, T. G. M., McEwen, S., Addington, J., Bearden, C. E., Cadenhead, K., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.023 · Cited by 599
Self-citationReview of Integrated Mental Health and Substance Abuse Treatment for Patients With Dual Disorders
Drake, R. E., Mercer-McFadden, C., Mueser, K. T., McHugo, G. J., & Bond, G. R. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033351 · Cited by 596
Dendritic spine pathology in schizophrenia
Glausier, J. R., & Lewis, D. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.044 · Cited by 581
Cannabis Use and Earlier Onset of Psychosis: A Systematic Meta-analysis
Large, M., Sharma, S., Compton, M. T., Slade, T., & Nielssen, O. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.5 · Cited by 563
Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 419
Prefrontal Cortical Dendritic Spine Pathology in Schizophrenia and Bipolar Disorder
Konopaske, G. T., Lange, N., Coyle, J. T., & Benes, F. M. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1582 · Cited by 379
Tardive dyskinesia and new antipsychotics
Correll, C. U., & Schenk, E. M. (2008) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3282f53132 · Cited by 367
Early adolescent cannabis exposure and positive and negative dimensions of psychosis
Stefanis, N. C., Delespaul, P., Henquet, C., Bakoula, C., Stefanis, C. N., & Van Os, J. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00806.x · Cited by 340
Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia
Kane, J. M., Agid, O., Baldwin, M. L., Howes, O., Lindenmayer, J.-P., Marder, S., Olfson, M., Potkin, S. G., & Correll, C. U. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18com12123 · Cited by 330
Self-citationWhat is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
Psychosocial Treatments to Promote Functional Recovery in Schizophrenia
Kern, R. S., Glynn, S. M., Horan, W. P., & Marder, S. R. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn177 · Cited by 267
Self-citationGene–Environment Interactions in Severe Mental Illness
Uher, R. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00048 · Cited by 251
Lewis, D. A., & Sweet, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37335 · Cited by 233
A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis
Turner, D. T., McGlanaghy, E., Cuijpers, P., van der Gaag, M., Karyotaki, E., & MacBeth, A. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx146 · Cited by 232
Assertive Community Treatment and Case Management for Schizophrenia
Scott, J. E., & Dixon, L. B. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.4.657 · Cited by 227
Schizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214
Self-citationDopamine D2 Receptor Occupancy and Clinical Effects: A Systematic Review and Pooled Analysis
Uchida, H., Takeuchi, H., Graff‐Guerrero, A., Suzuki, T., Watanabe, K., & Mamo, D. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182214aad · Cited by 161
Pharmacological Treatments for First-Episode Schizophrenia
Robinson, D. G., Woerner, M. G., Delman, H. M., & Kane, J. M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi032 · Cited by 150
Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., & for the METS Investigators (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12010127 · Cited by 145
Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss
Bennett, M. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.003 · Cited by 144
Effectiveness of individual placement and support supported employment for young adults
Bond, G. R., Drake, R. E., & Campbell, K. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12175 · Cited by 128
Cognitive Therapy of Schizophrenia: A New Therapy for the New Millennium
Beck, A. T., & Rector, N. A. (2000) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.2000.54.3.291 · Cited by 121
Ward, M. C., White, D. T., & Druss, B. G. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08657 · Cited by 118
Stone, J. M., Erlandsson, K., Arstad, E., Squassante, L., Teneggi, V., Bressan, R. A., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1047-x · Cited by 103
The Natural Course of Schizophrenia and Effective Maintenance Drug Treatment
Davis, J. M., & Andriukaitis, S. M. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198602001-00002 · Cited by 98
Solmi, M., Pigato, G., Kane, J. M., & Correll, C. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s133205 · Cited by 88
The Link Between the Immune System, Environment, and Psychosis
Radhakrishnan, R., Kaşer, M., & Gülöksüz, S. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx057 · Cited by 88
Neural circuit dysfunction in schizophrenia: Insights from animal models
Sigurdsson, T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.059 · Cited by 83
The Psychiatric Consequences of Cannabinoids
Aquino, J. P. D., Sherif, M. A., Radhakrishnan, R., Cahill, J. D., Ranganathan, M., & D’Souza, D. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.03.013 · Cited by 74
CBT for schizophrenia: a critical viewpoint
Jauhar, S., Laws, K. R., & McKenna, P. J. (2019) · Psychological Medicine · doi:10.1017/s0033291718004166 · Cited by 70
Tardive dyskinesia: eliminated, forgotten, or overshadowed?
Remington, G. J. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328017f6b1 · Cited by 68
Cited by
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Brannan, S. K., Sawchak, S., Miller, A. C., Lieberman, J. A., Paul, S. M., & Breier, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2017015 · Cited by 340
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
The role of histone modifications: from neurodevelopment to neurodiseases
Park, J., Lee, K., Kim, K., & Yi, S.-J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01078-9 · Cited by 297
International 22q11.2 Brain and Behavior Consortium, Davies, R. W., Fiksinski, A. M., Breetvelt, E. J., Williams, N. M., Hooper, S. R., Monfeuga, T., Bassett, A. S., Owen, M. J., Gur, R. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1103-1 · Cited by 139
Effects of inflammation on the kynurenine pathway in schizophrenia—a systematic review
Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., & Mulert, C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1721-z · Cited by 119
Metadata
- Authors
- Marder, S. R., & Cannon, T. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-31
- Volume
- 381
- Issue
- 18
- Pages
- 1753-1761
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4234860686
- Cited by
- 529
- References
- 46
- FWCI
- 33.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.